General Atlantic LLC Akero Therapeutics, Inc. Transaction History
General Atlantic LLC
- $3.5 Billion
- Q3 2024
A detailed history of General Atlantic LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, General Atlantic LLC holds 5,233,989 shares of AKRO stock, worth $148 Million. This represents 4.29% of its overall portfolio holdings.
Number of Shares
5,233,989
Previous 5,233,989
-0.0%
Holding current value
$148 Million
Previous $123 Million
22.29%
% of portfolio
4.29%
Previous 3.88%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$224 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$201 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$168 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$158 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.81MShares$108 Million0.01% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.32B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...